-
1Academic Journal
Συγγραφείς: M. Khanova, E. Grigoryev
Πηγή: Патология кровообращения и кардиохирургия, Vol 23, Iss 3 (2019)
Θεματικοί όροι: индуцированная иммуносупрессия, 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, системный воспалительный ответ, RD1-811, анти- PD-1-терапия, PD-1, Surgery, 16. Peace & justice, истощение Т-лимфоцитов, 3. Good health
-
2Academic Journal
Συγγραφείς: E. Grigoryev V., V. Matveeva G., D. Shukevich L., A. Radivilko S., E. Velikanova A., M. Khanova Yu., Е. Григорьев В., В. Матвеева Г., Д. Шукевич Л., А. Радивилко С., Е. Великанова А., М. Ханова Ю.
Συνεισφορές: Grant for government support to leading science schools of the Russian Federation (contest NSH-2018, NSH 2696.2018.7), Грант для государственной поддержки ведущих научных школ Российской Федерации (Конкурс НШ-2018, НШ 2696.2018.7)
Πηγή: Bulletin of Siberian Medicine; Том 18, № 1 (2019); 18-29 ; Бюллетень сибирской медицины; Том 18, № 1 (2019); 18-29 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2019-18-1
Θεματικοί όροι: systemic inflammatory reaction, persistent multi-organ failure, induced immunosup-pression, системная воспалительная реакция, персистирующая полиорганная недостаточность, индуцированная иммуносупрессия
Περιγραφή αρχείου: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/2167/1534; Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science. 2012; 335: 936–941. DOI:10.1126/science.1214935.; Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013; 13 (3): 260–268. DOI:10.1016/S1473-3099(13)70001-X.; Schefold J.C., Hasper D., Reinke P., Monneret G., Volk H.D. Consider delayed immunosuppression into the concept of sepsis. Crit Care Med. 2008; 36 (11): 3118. DOI:10.1097/CCM.0b013e31818bdd8f.; Ward N.S., Casserly B., Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin. Chest Med. 2008; 29 (4): 617–625. DOI:10.1016/j.ccm.2008.06.010.; Monneret G., Venet F., Kullberg B.J., Netea M.G. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med. Mycol. 2011; 49 (Suppl. 1): S17–S23. DOI:10.3109/13693786.2010.509744.; Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013; 13 (12): 862–874. DOI:10.1038/nri3552.; Delano M.J., Thayer T., Gabrilovich S., Kelly-Scumpia K.M., Winfield R.D., Scumpia P.O., Cuenca A.G., Warner E., Wallet S.M., Wallet M.A., O’Malley K.A., Ramphal R., Clare-Salzer M., Efron P.A., Mathews C.E., Moldawer L.L. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J. Immunol. 2011; 186 (1): 195–202. DOI:10.4049/jimmunol.1002104.; Stephan F., Yang K., Tankovic J., Soussy C.J., Dhonneur G., Duvaldestin P., Brochard L., Brun-Buisson C., Harf A., Delclaux C. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit. Care Med. 2002; 30 (2): 315–322.; Marini O., Costa S., Bevilacqua D., Calzetti F., Tamassia N., Spina C., De Sabata D., Tinazzi E., Lunardi C., Scupoli M.T., Cavallini C., Zoratti E., Tinazzi I., Marchetta A., Vassanelli A., Cantini M., Gandini G., Ruzzenente A., Guglielmi A., Missale F., Vermi W., Tecchio C., Cassatella M.A., Scapini P. Mature CD10+ and immature CD10- neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood. 2017; 129 (10): 1343–1356. DOI:10.1182/blood-2016-04-713206.; Orr Y., Taylor J.M., Bannon P.G., Geczy C., Kritharides L. Circulating CD10-/CD16 low neutrophils provide a quantitative index of active bone marrow neutrophil release. Br. J. Haematol. 2005; 131 (4): 508–519. DOI:10.1111/j.1365-2141.2005.05794.x.; Parihar A., Eubank T.D., Doseff A.I. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J. Innate. Immun. 2010; 2 (3): 204–215. DOI:10.1159/000296507.; Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009; 30 (10): 475–487. DOI:10.1016/j.it.2009.07.009.; Fumeaux T., Dufour J., Stern S., Pugin J. Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines. Intensive Care Med. 2004; 30 (11): 2028–2037. DOI:10.1007/s00134-004-2429-8.; Cavaillon J.M., Adrie C., Fitting C., Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J. Endotoxin Research. 2003; 9 (2): 101–107. DOI:10.1179/096805103125001487.; Lukaszewicz A.C., Grienay M., Resche-Rigon M., Pirracchio R., Faivre V., Boval B., Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Мed. 2009; 37 (10): 2746–2752. DOI:10.1097/CCM.; Delano M.J., Ward P.A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Invest. 2016; 126 (1): 23–31. DOI:10.1172/JCI82224.; Pachot A., Cazalis M.A., Venet F., Turrel F., Faudot C., Voirin N., Diasparra J., Bourgoin N., Poitevin F., Mougin B., Lepape A., Monneret G. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J. Immunol. 2008; 180 (9): 6421–6429. DOI:10.4049/jimmunol.180.9.6421.; Piani A., Hossle J.P., Birchler T., Siegrist C.A., Heumann D., Davies G., Loeliger S., Seger R., Lauener R.P. Expression of MHC class II molecules contributes to lipopolysaccharide responsiveness. Eur. J. Immunol. 2000; 30 (11): 3140–3146. DOI:10.1002/1521-4141(200011)30:113.0.CO;2-O.; Wolk K., Docke W.D., von Baehr V., Volk H.D., Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood. 2000; 96 (1): 218–223.; Wolk K., Höflich C., Zuckermann-Becker H., Döcke W.D., Volk H.D., Sabat R. Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit. Care Med. 2007; 35 (2): 458–467. DOI:10.1097/01.CCM.0000254724.54515.2F.; Venet F., Lukaszewicz A.C., Payen D., Hotchkiss R., Monneret G. Monitoring the immune response in sepsis: A rational approach to administration of immunoadjuvant therapies. Curr. Opin. Immunol. 2013; 25 (4): 477–483. DOI:10.1016/j.coi.2013.05.006.; Chenouard A., Braudeau C., Cottron N., Bourgoin P., Salabert N., Roquilly A., Josien R., Joram N., Asehnoune K. HLA-DR expression in neonates after cardiac surgery under cardiopulmonary bypass: a pilot study. Intensive Care Medicine Experimental. 2018; 6 (1): 1. DOI:10.1186/s40635-017-0166-x; Fabienne V., Cour M., Demaret J., Guillaume M., Laurent A. Decreased Monocyte HLA-DR Expression in Patients After Non-Shockable out-of-Hospital Cardiac Arrest. Shock. 2016; 46 (1): 33–36. DOI:10.1097/SHK.0000000000000561.; Umansky V., Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2013; 6 (2): 169–177. DOI:10.1007/s12307-012-0126-7.; Bronte V., Brandau S., Chen S.-H., Colombo M.P., Frey A.B., Greten T.F., Mandruzzato S., Murray P.J., Ochoa A., Ostrand-Rosenberg S., Rodriguez P.C., Sica A., Umansky V., Vonderheide R.H., Gabrilovich D.I. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature communications. 2016; 7: 12150. DOI:10.1038/ncomms12150.; Koehn B.H., Apostolova P., Haverkamp J.M., Miller J.S., McCullar V., Tolar J., Munn D.H., Murphy W.J., Brickey W.J., Serody J.S., Gabrilovich D.I., Bronte V., Murray P.J., Ting J.P., Zeiser R., Blazar B.R. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood. 2015; 126 (13): 1621–1628. DOI:10.1182/blood-2015-03-634691.; Uhel F., Azzaoui I., Grégoire M., Pangault C., Dulong J., Tadiй J.M., Gacouin A., Camus C., Cynober L., Fest T., Le Tulzo Y., Roussel M., Tarte K. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in septic patients. Am. J. Respir. Crit. Care Med. 2017; 196 (3): 315–327. DOI:10.1164/rccm.201606-1143OC.; Gey A. Tadie J.M., Caumont-Prim A., Hauw-Berlemont C., Cynober L., Fagon J.Y., Terme M., Diehl J.L., Delclaux C., Tartour E. Granulocytic Myeloid-Derived Suppressor Cells inversely correlate with plasma arginine and overall survival in critically ill patients. Clin. Exp. Immunol. 2015; 180 (2): 280–288. DOI:10.1111/cei.12567.; Tadié J.M., Cynober L., Peigne V., Caumont-Prim A., Neveux N., Gey A., Guerot E., Diehl J.L., Fagon J.Y., Tartour E., Delclaux C. Arginine administration to critically ill patients with a low nitric oxide fraction in the airways: a pilot study. Intensive Care Med. 2013; 39 (9): 1663–1665. DOI:10.1007/s00134-013-2984-y.; Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 2006; 311: 17–58.; Riccardi F., Della Porta M.G., Rovati B., Casazza A., Radolovich D., De Amici M., Danova M., Langer M. Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. Cytometry B Clin. Cytom. 2011; 80: 1421. DOI:10.1002/cyto.b.20540.; Guisset O., Dilhuydy M.S., Thiebaut R., Lefevre J., Camou F., Sarrat A., Gabinski C., Moreau J.F., Blanco P. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 2007; 33 (1): 148–152. DOI:10.1007/s00134-006-0436-7.; Hotchkiss R.S., Tinsley K.W., Swanson P.E., Grayson M.H., Osborne D.F., Wagner T.H., Cobb J.P., Coopersmith C., Karl I.E. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 2002; 168 (5): 2493–2500. DOI:10.4049/jimmunol.168.5.2493.; Pastille E., Didovic S., Brauckmann D., Rani M., Agrawal H., Schade F.U., Zhang Y., Flohe S.B. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J. Immunol. 2011; 186 (2): 977986. DOI:10.4049/jimmunol.1001147; Adrie C., Lugosi M., Sonneville R., Souweine B., Ruckly S., Cartier J.C., Garrouste-Orgeas M., Schwebel C., Timsit J.F. OUTCOMEREA study group. Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission. Annals of Intensive Care. 2017; 7: 30. DOI:10.1186/s13613-017-0242-0.; Inoue S., Suzuki-Utsunomiya K., Okada Y., Taira T., Iida Y., Miura N., Tsuji T., Yamagiwa T., Morita S., Chiba T., Sato T., Inokuchi S. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit. Care Med. 2013; 41 (3): 810–819. DOI:10.1097/CCM.0b013e318274645f.; De Jager C.P.C., van Wijk P.T.L., Mathoera R.B., de Jongh-Leuvenink J., van der Poll T., Wever P.C. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit. Care. 2010; 14 (5): R192. DOI:10.1186/cc9309.; Forel J.-M., Chiche L., Thomas G., Mancini J., Farnarier C., Cognet C., Guervilly C., Daumas A., Vély F., Xéridat F., Vivier E., Papazian L. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS One. 2012; 7(12): e50446. DOI:10.1371/journal.pone.0050446.; Souza-Fonseca-Guimaraes F., Parlato M., Fitting C., Cavaillon J.M., Adib-Conquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J. Immunol. 2012; 188 (12): 5850–5858. DOI:10.4049/jimmunol.1103616.; Grimaldi D., Le Bourhis L., Sauneuf B., Dechartres A., Rousseau C., Ouaaz F., Milder M., Louis D., Chiche J.D., Mira J.P., Lantz O., Pène F. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med. 2014; 40 (2): 192–201. DOI:10.1007/s00134-013-3163-x.; Venet F., Bohe J., Debard A.L., Bienvenu J., Lepape A., Monneret G. Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med. 2005; 33 (12): 2836–2840. DOI:10.1097/01.CCM.0000189745.66585.AE.; Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 2006; 6 (11): 813–822. DOI:10.1038/nri1943.; Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013; 13 (4): 227–242. DOI:10.1038/nri3405.; Zhang Y., Li J., Lou J., Zhou Y., Bo L., Zhu J., Zhu K., Wan X., Cai Z., Deng X. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit. Care. 2011; 15 (1): R70. DOI:10.1186/cc10059.; Huang X., Venet F., Wang Y.L., Lepape A., Yuan Z., Chen Y., Swan R., Kherouf H., Monneret G., Chung C.S., Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci USA. 2009; 106 (15): 6303–6308. DOI:10.1073/pnas.0809422106.; Guignant C., Lepape A., Huang X., Kherouf H., Denis L., Poitevin F., Malcus C., Chéron A., Allaouchiche B., Gueyffier F., Ayala A., Monneret G., Venet F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care. 2011; 15 (2): R99. DOI:10.1186/cc10112.; Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443 (7109): 350–354. DOI:10.1038/nature05115.; Huang X., Chen Y., Chung C.S., Yuan Z., Monaghan S.F., Wang F., Ayala A. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J. Immunol. 2014; 192 (3): 1091–1099. DOI:10.4049/jimmunol.1302252.; Goyert S.M., Silver J. Editorial: PD-1, a new target for sepsis treatment: better late than never. J. Leukoc. Biol. 2010; 88: 225–226. DOI:10.1189/jlb.0410240.; Wick M., Kollig E., Muhr G., Koller M. The potential pattern of circulating lymphocytes TH1/TH2 is not altered after multiple injuries. Arch. Surg. 2000; 135 (11): 1309–1314. DOI:10.1001/archsurg.135.11.1309.; Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J.D., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998; 188 (12): 2205–2213. DOI:10.1084/jem.188.12.2205.; Kuethe J.W., Mintz-Cole R., Johnson B.L. 3rd, Midura E.F., Caldwell C.C., Schneider B.S. Assessing the Immune Status of Critically Ill Trauma Patients by Flow Cytometry. Nurs. Res. 2014; 63 (6): 426–434. DOI:10.1097/NNR.0000000000000061.; Monneret G., Debard A.L., Venet F., Bohe J., Hequet O., Bienvenu J., Lepape A. Marked elevation of human circulating CD41CD251 regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 2003; 31 (7): 2068– 2071. DOI:10.1097/01.CCM.0000069345.78884.0F.; Kessel A., Bamberger E., Masalha M., Toubi E. The role of T regulatory cells in human sepsis. J. Autoimmun. 2009; 32 (3–4): 211–215. DOI:10.1016/j.jaut.2009.02.014.; Chen K., Zhou Q.X., Shan H.W., Li W.F., Lin Z.F. Prognostic value of CD4(1)CD25(1) Tregs as a valuable biomarker for patients with sepsis in ICU. World. J. Emerg. Med. 2015; 6 (1): 40–43. DOI:10.5847/wjem.j.1920-8642.2015.01.007.; Huang H., Xu R., Lin F., Bao C., Wang S., Ji C., Li K., Jin L., Mu J., Wang Y., Li L., Sun L., Xu B., Zhang Z., Wang F.S. High circulating CD39(+) regulatory T cells predict poor survival for sepsis patients. Int. J. Infect. Dis. 2015; 30: 57–63. DOI:10.1016/j.ijid.2014.11.006.; https://bulletin.tomsk.ru/jour/article/view/2167
-
3Academic Journal
Συγγραφείς: Moskvichov, E. P.
Πηγή: Zaporozhye мedical journal; No. 2 (2013): Zaporozhye medical journal ; Запорожский медицинский журнал; № 2 (2013): Запорізький медичний журнал ; Запорізький медичний журнал; № 2 (2013): Запорізький медичний журнал ; 2310-1210 ; 2306-4145
Θεματικοί όροι: doxorubicine-induced immunosuppression, Amixin, Imunofan, Polyoxidonium, cytokine profile, доксорубицин-индуцированная иммуносупрессия, амиксин, имунофан, полиоксидоний, цитокиновый профиль, доксорубіцин-індукована імуносупресія, аміксин, імунофан, поліоксидоній, цитокіновий профіль
Περιγραφή αρχείου: application/pdf
Relation: http://zmj.zsmu.edu.ua/article/view/15593/13393; http://zmj.zsmu.edu.ua/article/view/15593
Διαθεσιμότητα: http://zmj.zsmu.edu.ua/article/view/15593
-
4Academic Journal
Συγγραφείς: Москвичов, Є.
Θεματικοί όροι: ДОКСОРУБіЦИН-іНДУКОВАНА іМУНОСУПРЕСіЯ, АМіКСИН, іМУНОФАН, ПОЛіОКСИДОНіЙ, ЦИТОКіНОВИЙ ПРОФіЛЬ, ДОКСОРУБИЦИН-ИНДУЦИРОВАННАЯ ИММУНОСУПРЕССИЯ, АМИКСИН, ИМУНОФАН, ПОЛИОКСИДОНИЙ, ЦИТОКИНОВЫЙ ПРОФИЛЬ
Περιγραφή αρχείου: text/html
-
5Academic Journal
Συγγραφείς: Лебединская, Е., Лосева, Любовь, Гусин, Д., Ахматова, Н., Семёнова, И., Лебединская, О.
Θεματικοί όροι: ЦИКЛОФОСФАН, ЦИТОСТАТИКИ, ИНДУЦИРОВАННАЯ ИММУНОСУПРЕССИЯ, ИММУНОВАК ВП-4, ЛИМФОЦИТЫ, ИММУНОФЕНОТИП, ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ
Περιγραφή αρχείου: text/html
-
6Academic Journal
Συγγραφείς: Moskvichov, E. P.
Πηγή: Zaporožskij Medicinskij Žurnal, Iss 2, Pp 32-35 (2013)
Zaporozhye мedical journal; No. 2 (2013): Zaporozhye medical journal
Запорожский медицинский журнал; № 2 (2013): Запорізький медичний журнал
Запорізький медичний журнал; № 2 (2013): Запорізький медичний журналΘεματικοί όροι: имунофан, цитокиновый профиль, доксорубицин-индуцированная иммуносупрессия, полиоксидоний, імунофан, doxorubicine-induced immunosuppression, аміксин, цитокіновий профіль, cytokine profile, Polyoxidonium, 3. Good health, амиксин, поліоксидоній, Medicine, Amixin, доксорубіцин-індукована імуносупресія, Imunofan
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://zmj.zsmu.edu.ua/article/view/15593
-
7Academic Journal
Πηγή: Российский биотерапевтический журнал.
Θεματικοί όροι: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, ЦИКЛОФОСФАН, ЦИТОСТАТИКИ, ИНДУЦИРОВАННАЯ ИММУНОСУПРЕССИЯ, ИММУНОВАК ВП-4, ЛИМФОЦИТЫ, ИММУНОФЕНОТИП, ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ, 3. Good health
Περιγραφή αρχείου: text/html
-
8Academic Journal
Συγγραφείς: Москвичёв, Е. П., Рожковский, Я. В., Moskvichov, E. P., Rozhkovsky, Ya. V.
Θεματικοί όροι: экспериментальная доксорубин-индуцированная иммуносупрессия, амиксин, механизмы иммуномодулирующего действия, experimental doxorubin-induced immunosuppression, amixin, mechanisms immunomodulatory action
Περιγραφή αρχείου: application/pdf
Διαθεσιμότητα: https://repo.odmu.edu.ua:443/xmlui/handle/123456789/8424
-
9Academic Journal
Συγγραφείς: Москвичов, Є. П., Рожковський, Я. В., Moskvychov, Ye. P., Rozhkovsky, Ya. V.
Θεματικοί όροι: экспериментальная доксорубицин-индуцированная иммуносупрессия, амиксин, механизмы иммуномодулирующего действия
Περιγραφή αρχείου: application/pdf
Διαθεσιμότητα: http://repo.odmu.edu.ua:80/xmlui/handle/123456789/2350
